GLOW (GHK-Cu + TB-500 + BPC-157)
A 70 mg multi-peptide research formulation combining GHK-Cu, TB-500, and BPC-157 in a fixed 5:1:1 ratio for tissue repair investigations.
Mechanism
The blend targets coordinated tissue regeneration by integrating GHK-Cu-mediated matrix metalloproteinase and collagen regulation, TB-500-driven actin sequestering for cell motility, and BPC-157-facilitated angiogenic and nitric oxide cytoprotective cascades.
Dosing
2,330 mcg total blend once daily for 4 weeks, then 2–4 weeks off.
Reconstitution
Add 3.0 mL of bacteriostatic water to the 70 mg combined vial to achieve a final concentration of approximately 23.33 mg/mL total blend (~16.67 mg/mL GHK-Cu, ~3.33 mg/mL TB-500, and ~3.33 mg/mL BPC-157).
Storage
Lyophilized: store at −20 °C; after reconstitution, refrigerate at 2–8 °C and do not freeze.
Mix & measure GLOW (GHK-Cu + TB-500 + BPC-157)
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure GLOW (GHK-Cu + TB-500 + BPC-157)
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 30.0
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Week 1 - 4 (Active Cycle) | 2,330 mcg total blend once daily | 10 units (0.10 mL) |
| Week 5 - 8 (Washout / Off Period) | 0 mcg (Cessation period) | 0 units (0.00 mL) |
Reconstitution Steps
- 1
Remove the lyophilized 70 mg peptide vial from the −20 °C freezer and allow it to equilibrate to room temperature for 15 to 20 minutes.
- 2
Sterilize the rubber septum of both the peptide vial and the bacteriostatic water vial using a fresh 70% isopropyl alcohol swab and allow them to air-dry completely.
- 3
Using a sterile reconstitution syringe, draw 3.0 mL of bacteriostatic water from the diluent vial.
- 4
Insert the needle at a slight angle and inject the 3.0 mL of bacteriostatic water slowly down the inside glass wall of the peptide vial to avoid agitation and foaming.
- 5
Gently swirl and roll the vial between your palms until the powder is fully dissolved into a clear, characteristic light-blue solution; never shake vigorously.
- 6
Affix a research label noting the reconstitution date, total concentration (23.3 mg/mL total blend), and immediately store in the dark at 2–8 °C.
Supplies Needed
Peptide Vial
Provides 70 mg total lyophilized blend (50 mg GHK-Cu, 10 mg TB-500, 10 mg BPC-157); 1 vial provides ~30 daily doses of 2,330 mcg.
Insulin Syringes (U-100)
Used for precise micro-volume administration; approximately 30 sterile U-100 syringes (0.5 mL or 0.3 mL barrel) are required for a standard 4-week research protocol.
Bacteriostatic Water
Serves as the sterile, preserved diluent; exactly 3.0 mL is drawn from a multi-dose vial to reconstitute the 70 mg peptide blend.
Alcohol Swabs
Used to maintain aseptic conditions on vial septa and injection surfaces; roughly 60 to 70 individually wrapped 70% isopropyl alcohol pads are needed.
Why researchers study it
Tissue repair & recovery pathways
Skin & collagen synthesis support
Anti-inflammatory & cytoprotective cascades
Fixed-ratio multi-peptide synergy models
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
The GLOW blend is an investigational multi-peptide formulation co-lyophilized in a fixed 5:1:1 stoichiometric ratio, containing 50 mg of copper tripeptide-1 (GHK-Cu), 10 mg of the synthetic actin-sequestering fragment TB-500, and 10 mg of the pentadecapeptide BPC-157. Formulating these distinct compounds into a single multi-dose unit provides experimental convenience for exploring concurrent cellular pathways involved in tissue remodeling, angiogenic signaling, and extracellular matrix stabilization. Each constituent brings an independent mechanism to the mixture. GHK-Cu acts via copper transport to upregulate procollagen expression, modulate matrix metalloproteinases, and exhibit antioxidant activity. TB-500 mimics key regions of thymosin beta-4 to accelerate cellular migration and tissue restitution via actin sequestering, while BPC-157 stimulates the nitric oxide signaling cascade and vascular endothelial growth factor (VEGF) release to promote cytoprotection and microvascular repair. This composite blend is strictly designed for in vitro and preclinical laboratory research to evaluate coordinated regenerative signaling networks. Co-formulation in a single lyophilized vial locks the stoichiometric ratios together, which facilitates fixed-ratio trials while precluding independent dosage titration of the individual peptides. The mixture has not been clinically evaluated or approved for human therapeutic use.
References
- 1.Pickart L, Vasquez-Soltero JM, Margolina A, Int J Mol Sci, 2018 — Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data
- 2.Sikiric P et al., Curr Pharm Des, 2018 — Stable gastric pentadecapeptide BPC 157, novel therapy in gastrointestinal tract and beyond
- 3.Sosne G et al., Expert Opin Biol Ther, 2010 — Thymosin beta 4: a novel corneal wound healing agent with multi-factorial mechanisms of action
- 4.Chang CH et al., J Orthop Res, 2011 — The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allChonluten 20mg
Chonluten is a synthetic tripeptide bioregulator investigated for its tissue-specific role in modulating bronchopulmonary gene expression.
View ProtocolEcnoglutide 10mg
A novel cAMP-biased, long-acting GLP-1 receptor agonist studied for glycemic management and weight reduction.
View ProtocolTesamorelin 20mg
A stabilized GHRH analog investigated for triggering endogenous growth hormone pulses and targeted reduction of visceral adipose tissue.
View Protocol